Management of residual mass in nonseminomatous germ cell tumors following chemotherapy
Advanced stage nonseminomatous testis cancer is commonly treated with chemotherapy and surgical resection. Patients with retroperitoneal residual masses >1cm following induction chemotherapy with normalized tumor markers should undergo a post-chemotherapy retroperitoneal lymph node dissection. Po...
Main Authors: | Siamak Daneshmand, Hooman Djaladat, Craig Nichols |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2011-08-01
|
Series: | Therapeutic Advances in Urology |
Online Access: | https://doi.org/10.1177/1756287211418721 |
Similar Items
-
Management of post-chemotherapy residual mass in patients with metastatic nonseminomatous germ cell tumors of the testis
by: John P Fitzgerald, et al.
Published: (2010-01-01) -
Surgical controversies in the management of post-chemotherapy nonretroperitoneal residual disease in metastatic nonseminomatous germ cell tumors
by: Durgatosh Pandey, et al.
Published: (2016-01-01) -
Is the percentage of teratoma in the orchiectomy specimen predictive of teratoma in retroperitoneal residual masses after chemotherapy in nonseminomatous germ cell tumors?
by: H. Boussaffa, et al.
Published: (2020-11-01) -
Nonseminomatous Germ-Cell Tumor Presenting as Bilateral Adrenal Masses
by: Neelam Baral, MD, et al.
Published: (2021-01-01) -
Retroperitoneal lymph node dissection for residual masses after chemotherapyin nonseminomatous germ cell testicular tumor
by: Tanguay Simon, et al.
Published: (2010-11-01)